Stock Fundamentals

FBIO.US Logo

FBIO.US - Current Price

$2.59

Company Information

Company Name
Fortress Biotech Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US34960Q3074
CIK: 0001429260
CUSIP: 21976U109
Currency: USD
Full Time Employees: 101
Phone: 781 652 4500
Fiscal Year End: December
IPO Date: Nov 17, 2011
Description:

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Address:

1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154

Directors & Officers

Name Title Year Born
Dr. Lindsay Allan Rosenwald M.D. Executive Chairman, President & CEO 1955
Mr. David Jin CFO & Head of Corporate Development 1990
Dr. Xiaoqin Lu M.D. Chief Strategy Officer 1975
Mr. Michael S. Weiss Esq., J.D. Executive Vice Chairman of Strategic Development & Director 1966
Mr. Samuel Berry General Counsel & Corporate Secretary NA
Dr. George C. Avgerinos Ph.D. Senior Vice President of Biologics Operations 1954

Shares Statistics

Shares Outstanding: 31.04M
Shares Float: 23.12M
% Insiders: 2,011.60%
% Institutions: 1,504.50%
Short % Float: 14.91%

Valuation Metrics

Enterprise Value: $62.78M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $80.39M
EBITDA: $-80.00M
PEG Ratio: $-0.10
Book Value: $1.80
Earnings/Share: $-0.12
Profit Margin: 6.40%
Operating Margin: -38.63%
ROA (TTM): -34.29%
ROE (TTM): -205.29%
Revenue (TTM): $62.30M
Revenue/Share (TTM): $2.28
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 20.50%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

Date EPS Actual EPS Estimate Difference Surprise %
Sep 30, 2025 0.11 -0.01 N/A 120,000.00%
Jun 30, 2025 0.45 0.07 N/A 54,285.71%
Mar 31, 2025 -0.48 -0.44 N/A -909.09%
Dec 31, 2024 -0.30 -0.75 N/A 6,009.33%
Sep 30, 2024 -0.76 -0.27 N/A -18,148.15%
Jun 30, 2024 -0.73 -1.22 N/A 4,016.39%
Mar 31, 2024 -1.03 -1.73 N/A 4,046.24%
Dec 31, 2023 -1.28 -1.97 N/A 3,502.54%
Sep 30, 2023 -0.94 -3.21 N/A 7,071.65%
Jun 30, 2023 -0.24 -0.23 N/A -434.78%
Mar 31, 2023 -0.21 -0.20 N/A -500.00%
Dec 31, 2022 -0.30 -0.22 N/A -3,636.36%
Sep 30, 2022 -0.25 -0.27 N/A 740.74%
Jun 30, 2022 -0.24 -0.21 N/A -1,428.57%
Mar 31, 2022 -0.18 -0.28 N/A 3,571.43%
Dec 31, 2021 -0.38 0.18 N/A -31,111.11%
Sep 30, 2021 -0.14 -0.08 N/A -7,500.00%
Jun 30, 2021 -0.29 -0.12 N/A -14,166.67%
Mar 31, 2021 -0.11 -0.11 N/A 0.00%
Dec 31, 2020 -0.05 -0.14 N/A 6,428.57%
Sep 30, 2020 -0.20 -0.22 N/A 909.09%
Jun 30, 2020 -0.19 -0.27 N/A 2,962.96%
Mar 31, 2020 -0.19 -0.23 N/A 1,739.13%
Dec 31, 2019 -0.27 -0.31 N/A 1,290.32%
Sep 30, 2019 -0.22 -0.30 N/A 2,666.67%
Jun 30, 2019 -0.24 -0.46 N/A 4,782.61%
Mar 31, 2019 -0.27 -0.58 N/A 5,344.83%
Dec 31, 2018 -0.58 -0.58 N/A 0.00%
Sep 30, 2018 -0.37 -0.55 N/A 3,272.73%
Jun 30, 2018 -0.50 -0.59 N/A 1,525.42%
Mar 31, 2018 -0.49 -0.43 N/A -1,395.35%
Dec 31, 2017 -0.22 -0.63 N/A 6,507.94%
Sep 30, 2017 -0.67 -0.42 N/A -5,952.38%
Jun 30, 2017 -0.43 -0.29 N/A -4,827.59%
Mar 31, 2017 -0.30 -0.36 N/A 1,666.67%
Dec 31, 2016 -0.44 -0.31 N/A -4,193.55%
Sep 30, 2016 -0.32 -0.20 N/A -6,000.00%
Jun 30, 2016 -0.31 -0.29 N/A -689.66%
Mar 31, 2016 -0.31 N/A N/A N/A
Dec 31, 2015 -0.31 -0.09 N/A -24,444.44%
Sep 30, 2015 -0.46 -0.13 N/A -25,384.62%
Jun 30, 2015 -0.12 -0.14 N/A 1,428.57%
Mar 31, 2015 -0.12 -0.11 N/A -909.09%
Dec 31, 2014 -0.10 N/A N/A N/A
Sep 30, 2014 -0.13 N/A N/A N/A
Jun 30, 2014 -0.13 -0.18 N/A 2,777.78%
Mar 31, 2014 -0.21 -0.20 N/A -500.00%
Dec 31, 2013 -0.27 -0.22 N/A -2,272.73%
Sep 30, 2013 -0.24 -0.31 N/A 2,258.06%
Jun 30, 2013 -0.38 -0.34 N/A -1,176.47%
Mar 31, 2013 -0.35 -0.30 N/A -1,666.67%
Dec 31, 2012 -0.32 -0.28 N/A -1,428.57%
Sep 30, 2012 -0.24 -0.28 N/A 1,428.57%
Jun 30, 2012 -0.34 -0.40 N/A 1,500.00%
Mar 31, 2012 -0.35 -0.31 N/A -1,290.32%
Dec 31, 2011 -0.52 -0.32 N/A -6,250.00%
Sep 30, 2011 -7.18 N/A N/A N/A

Balance Sheet (Yearly)

Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $57.26M $N/A $144.22M $145.87M $22.74M
2023-12-31 $80.93M $N/A $167.53M $165.94M $22.54M
2022-12-31 $178.27M $N/A $294.30M $244.28M $41.72M
2021-12-31 $305.74M $N/A $396.50M $170.63M $108.67M
2020-12-31 $233.35M $N/A $328.83M $131.84M $100.34M
2019-12-31 $136.86M $N/A $226.42M $153.89M $26.22M
2018-12-31 $65.51M $N/A $140.99M $121.25M $1.85M
2017-12-31 $113.92M $N/A $245.95M $125.45M $52.57M
2016-12-31 $88.29M $N/A $170.73M $87.76M $38.50M
2015-12-31 $98.18M $N/A $118.61M $34.34M $56.85M
2014-12-31 $49.76M $N/A $89.33M $18.81M $70.52M
2013-12-31 $99.52M $N/A $100.58M $19.30M $81.28M
2012-12-31 $40.20M $N/A $40.99M $18.96M $22.03M
2011-12-31 $23.16M $N/A $23.38M $4.24M $19.13M
2010-12-31 $14.86M $N/A $14.94M $1.56M $13.38M
2009-12-31 $1.51M $N/A $1.69M $11.78M $-10.09M
2008-12-31 $N/A $N/A $N/A $N/A $N/A

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Sep 23, 2024 N/A N/A N/A N/A N/A N/A
Jul 11, 2024 N/A N/A N/A N/A N/A N/A
Jul 10, 2024 N/A N/A N/A N/A N/A N/A
Jul 08, 2024 N/A N/A N/A N/A N/A N/A
Jun 28, 2024 N/A N/A N/A N/A N/A N/A
May 20, 2024 N/A N/A N/A N/A N/A N/A
May 16, 2024 N/A N/A N/A N/A N/A N/A
Jan 05, 2024 N/A N/A N/A N/A N/A N/A
Nov 14, 2023 N/A N/A N/A N/A N/A N/A
Nov 14, 2023 N/A N/A N/A N/A N/A N/A
Sep 26, 2023 N/A N/A N/A N/A N/A N/A
Aug 17, 2023 N/A N/A N/A N/A N/A N/A
Dec 01, 2022 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist